Biocon Biologics UK Limited Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Biocon Biologics UK Limited Pharmaceutical Import Records from India — 3 Products, $2.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biocon Biologics UK Limited — Pharmaceutical Importer Profile (2026) | 3 Products, $2.4M Trade | TransData Nexus

Biocon Biologics UK Limited

Pharmaceutical Importer · Netherlands · Advanced Oncology Focus · $2.4M Total Trade · DGFT Verified

Biocon Biologics UK Limited is a pharmaceutical importer based in Netherlands with a total trade value of $2.4M across 3 products in 2 therapeutic categories. Based on 48 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Biocon Biologics UK Limited sources from 1 verified Indian supplier, with Biocon Biologics India Limited accounting for 100.0% of imports.

Biocon Biologics UK Limited — Import Portfolio & Supplier Network

Biocon Biologics UK Limited import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Biocon Biologics UK Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Biocon Biologics India Limited	$2.2M	50	100.0%

Biocon Biologics UK Limited sources from 1 verified Indian supplier across 23 distinct formulations. The sourcing is highly concentrated — Biocon Biologics India Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Biocon Biologics UK Limited Import?

Formulation	Value	Ships
Abevmy 25 MG/ML	$566.1K	12
Fulphila 6MG/0.6ML	$330.0K	7
Trastuzumab for	$150.0K	4
Tuzepta 440MG	$100.0K	4
Abevmy 25 MG/ML	$100.0K	2
Ogivri tm 440 -trastuzumab	$100.0K	2
Trastuzumab for	$100.0K	2
Ogivri tm 150 -trastuzumab	$88.5K	2
Demo syringe	$50.0K	1
Neucyte 6MG/0.6ML	$50.0K	1
Zedora 440MG -trastuzumab	$50.0K	1
Bevamyl 25 MG/ML	$50.0K	1
Bevacizumab	$50.0K	1
Trastuzumab for injection	$50.0K	1
Trastuzumab lyophilized	$50.0K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bevacizumab	Advanced Oncology	$900.0K	18	1.9%	3
2	Ras	Ayurvedic & Herbal Products	$750.0K	15	0.2%	18
3	Trastuzumab	Advanced Oncology	$750.0K	15	1.0%	6

Biocon Biologics UK Limited imports 3 pharmaceutical products across 2 categories into Netherlands totaling $2.4M.

Biocon Biologics UK Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Biocon Biologics UK Limited, now known as Biocon Biologics UK PLC following its re-registration on October 29, 2025, is a public limited company incorporated on July 27, 2022. (find-and-update.company-information.service.gov.uk) The company is headquartered at 16 Great Queen Street, Covent Garden, London, United Kingdom, WC2B 5AH. It operates as a pharmaceutical importer and buyer, focusing on the acquisition of finished pharmaceutical formulations from India. Biocon Biologics UK PLC is a subsidiary of Biocon Biologics Limited, which is itself a subsidiary of Biocon Limited, India's largest biopharmaceutical company. In the Netherlands, Biocon Biologics UK PLC plays a significant role in the pharmaceutical distribution network, importing a range of biologic and biosimilar products to meet the healthcare needs of the Dutch market.

2Distribution Network

Biocon Biologics UK PLC's distribution network in the Netherlands is strategically designed to ensure efficient delivery of pharmaceutical products. While specific warehouse locations and logistics capabilities are not publicly disclosed, the company's operations are supported by its parent company's global infrastructure. Biocon Limited has a significant presence in Europe, including offices in the United Kingdom and Ireland, which likely facilitate the distribution of products to the Netherlands. The company's logistics operations are designed to ensure timely and compliant delivery of pharmaceutical products across the Netherlands and potentially to other European markets.

3Industry Role

In the Netherlands' pharmaceutical supply chain, Biocon Biologics UK PLC functions primarily as a pharmaceutical importer and buyer. The company imports finished pharmaceutical formulations from India, focusing on biologic and biosimilar products. By sourcing these products, Biocon Biologics UK PLC contributes to the availability of affordable and innovative therapies in the Dutch market, addressing the healthcare needs of patients. The company's role is crucial in ensuring a steady supply of high-quality pharmaceutical products, thereby supporting the Dutch healthcare system's objectives of providing accessible and effective treatments.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Biocon Biologics UK Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Biocon Biologics UK PLC's sourcing strategy exhibits a high degree of concentration, with all 48 shipments from India originating from a single supplier, Biocon Biologics India Limited, amounting to a total import value of $2.4 million USD. This single-source dependency indicates a strategic choice to maintain a consistent and reliable supply chain, leveraging the established relationship with its parent company's manufacturing facilities. The shipment data reveals a stable and ongoing relationship, as evidenced by the consistent import activity over the period from 2022 to 2026. However, this concentration also presents potential risks, such as supply chain disruptions due to unforeseen events affecting the sole supplier. To mitigate such risks, it would be prudent for Biocon Biologics UK PLC to consider diversifying its supplier base while maintaining the strategic advantages of its current sourcing model.

2Supply Chain Resilience

Biocon Biologics UK PLC's supply chain resilience is closely tied to its relationship with Biocon Biologics India Limited, its sole supplier. The company's reliance on a single supplier for all its imports from India suggests a streamlined and efficient supply chain. However, this concentration may expose the company to risks associated with supply chain disruptions, such as production delays or logistical challenges. The absence of publicly available information regarding backup suppliers or alternative sourcing strategies indicates a potential area for improvement in enhancing supply chain resilience. Additionally, the company's focus on a limited number of formulations may limit its ability to adapt to changing market demands. To strengthen its supply chain resilience, Biocon Biologics UK PLC could explore partnerships with additional suppliers and diversify its product portfolio, ensuring a more robust response to market fluctuations and potential disruptions.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the regulatory authority overseeing pharmaceutical imports is the Dutch Medicines Evaluation Board (CBG-MEB), which operates under the Ministry of Health, Welfare, and Sport (VWS). The key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for the import, distribution, and sale of medicinal products. The marketing authorization pathway for Indian generics involves obtaining a marketing authorization from the CBG-MEB, ensuring that imported products meet the safety, efficacy, and quality standards required for the Dutch market. This process includes a thorough evaluation of the product's documentation, manufacturing processes, and compliance with Good Manufacturing Practice (GMP) standards.

2Import Licensing & GMP

Import licensing requirements in the Netherlands stipulate that companies involved in the importation of medicinal products must obtain the necessary permits from the CBG-MEB. This includes a manufacturer's permit for the preparation and importation of medicines from outside the European Economic Area (EEA). Additionally, companies must ensure that their suppliers hold valid GMP certificates recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S certifications. Wholesale distribution authorization is also required to distribute medicinal products within the Netherlands. These regulatory measures are in place to ensure that imported pharmaceutical products meet the required safety, efficacy, and quality standards, safeguarding public health. (business.gov.nl)

Biocon Biologics UK Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Biocon Biologics UK PLC's product strategy focuses on importing biologic and biosimilar products, particularly in the therapeutic areas of advanced oncology and Ayurvedic & herbal products. The company's import data indicates a significant emphasis on advanced oncology, accounting for 68.8% of the total import value, with products like Bevacizumab and Trastuzumab being key contributors. The inclusion of Ayurvedic & herbal products, comprising 31.3% of the import value, reflects a strategic decision to diversify the product portfolio and cater to a broader patient demographic seeking alternative and complementary therapies. This product mix aligns with the growing demand for personalized and holistic treatment options in the Dutch market.

2Sourcing Profile

Biocon Biologics UK PLC's sourcing strategy is centered on importing finished pharmaceutical formulations from India, with a particular focus on biologic and biosimilar products. The company's reliance on a single supplier, Biocon Biologics India Limited, suggests a streamlined procurement process aimed at ensuring consistency and quality. This approach allows the company to leverage the manufacturing capabilities and expertise of its parent company, Biocon Limited, to meet the specific needs of the Dutch market. While this strategy offers operational efficiencies, it also highlights the importance of maintaining a robust and resilient supply chain to mitigate potential risks associated with supplier dependency.

Frequently Asked Questions — Biocon Biologics UK Limited

What products does Biocon Biologics UK Limited import from India?

Biocon Biologics UK Limited imports 3 pharmaceutical products across 2 categories. Top imports: Bevacizumab ($900.0K), Ras ($750.0K), Trastuzumab ($750.0K).

Who supplies pharmaceuticals to Biocon Biologics UK Limited from India?

Biocon Biologics UK Limited sources from 1 verified Indian suppliers. The primary supplier is Biocon Biologics India Limited (100.0% of imports, $2.2M).

What is Biocon Biologics UK Limited's total pharmaceutical import value?

Biocon Biologics UK Limited's total pharmaceutical import value from India is $2.4M, based on 48 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Biocon Biologics UK Limited focus on?

Biocon Biologics UK Limited imports across 2 categories. The largest: Advanced Oncology (68.8%), Ayurvedic & Herbal Products (31.3%).

Get Full Biocon Biologics UK Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Biocon Biologics UK Limited

Biocon Biologics UK Limited — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Biocon Biologics UK Limited?

What Formulations Does Biocon Biologics UK Limited Import?

What Products Does Biocon Biologics UK Limited Import?

Top Products by Import Value

Biocon Biologics UK Limited Therapeutic Categories — 2 Specializations